Customized Citrate Anticoagulation versus No Anticoagulant in Continuous Venovenous Hemofiltration in Critically ill patients with Acute Kidney Injury
- Conditions
- Filter clotting in patients with acute kidney injury requiring continuous venovenous hemofiltrationCVVHregional citrate anticoagulationcustomized citrate-based replacement fluidcitrate accumulationbleeding
- Registration Number
- TCTR20210924001
- Lead Sponsor
- Faculty of Medicine Siriraj Hospital , Mahidol University ,Thailand
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Terminated (Halted Prematurely)
- Sex
- All
- Target Recruitment
- 78
1.Age > 18 yours
2.Critically ill patients with acute kidney injury who admitted to ICU
3.Fullfils at least ONE of the following for initiating Continuous renal replacement therapy (CRRT)
3.1 Refractory volume overload
3.2 Refractory hyperkalemia
3.3 Uremic symptom
3.4 Refractory metabolic acidosis
1.Patient who need systemic anticoagulation
2.Chronic renal replacement therapy
3.Pregnancy , Breast feeding
4.Post hepatic resection , severe acute liver failure , waiting list for liver transplantation
5.Serum Na > 160 mEq/L or Serum HCO3 > 40 mEq/L or pH >7.5 before renal replacement therapy
6.Active bleeding
7.Persistent symptomatic hypocalcemia or total calcium / ionized calcium ratio >2.5
8.Refuse to participate
9.Citrate allergy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method the survival time of the first filter (1st circuit lifespan) until change filter or 72 hours continuous data (hour),the number of filters used within the first 72 hours continuous data
- Secondary Outcome Measures
Name Time Method 14-d Mortality 14 days categorical data,28-d Mortality 28 days categorical data,Renal recovery 28 days categorical data,Length of ICU stay until discharge from ICU continuous data,Adverse event 28 days categorical data